| Name | Title | Contact Details |
|---|
Project Mend is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Signify Health exists to drive more healthy, happy days at home. That`s why we`re committed to accelerating the movement to value-based care, transforming how care is paid for and delivered, and sharing accountability for driving better outcomes for the individuals and families we all serve. Today, Signify Health is privileged to impact the lives of millions of people every year. Our high-performance provider and community networks—which includes the nation`s largest field-based network of doctors and nurse practitioners—reaches and engages people anywhere in the U.S. With powerful analytics and clinical expertise, we support individuals` health journeys from the acute care facility to the ideal next site of care and all the way to a place of residence, helping them get home sooner and stay there longer. This is how we`re transforming a fragmented healthcare system into one that`s value-based, human-centered, and drives more healthy and happy days at home.
Medical Professionals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
J D Imaging Svc is a Mundelein, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.